CN113614531A - 检测神经变性疾病的方法 - Google Patents

检测神经变性疾病的方法 Download PDF

Info

Publication number
CN113614531A
CN113614531A CN202080012032.7A CN202080012032A CN113614531A CN 113614531 A CN113614531 A CN 113614531A CN 202080012032 A CN202080012032 A CN 202080012032A CN 113614531 A CN113614531 A CN 113614531A
Authority
CN
China
Prior art keywords
exosome
biomarker
bound
subject
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080012032.7A
Other languages
English (en)
Chinese (zh)
Inventor
邵慧琳
Z·J·C·林
张岩
L-H·C·陈
骆子品
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nat University Hospital Singapore Pte Ltd
National University of Singapore
Original Assignee
Nat University Hospital Singapore Pte Ltd
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat University Hospital Singapore Pte Ltd, National University of Singapore filed Critical Nat University Hospital Singapore Pte Ltd
Priority to CN202510593175.6A priority Critical patent/CN120870569A/zh
Publication of CN113614531A publication Critical patent/CN113614531A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • G01N21/554—Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080012032.7A 2019-01-31 2020-01-30 检测神经变性疾病的方法 Pending CN113614531A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510593175.6A CN120870569A (zh) 2019-01-31 2020-01-30 检测神经变性疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201900940Y 2019-01-31
SG10201900940Y 2019-01-31
PCT/IB2020/050764 WO2020157705A1 (en) 2019-01-31 2020-01-30 Method of detecting a neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510593175.6A Division CN120870569A (zh) 2019-01-31 2020-01-30 检测神经变性疾病的方法

Publications (1)

Publication Number Publication Date
CN113614531A true CN113614531A (zh) 2021-11-05

Family

ID=71841387

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080012032.7A Pending CN113614531A (zh) 2019-01-31 2020-01-30 检测神经变性疾病的方法
CN202510593175.6A Pending CN120870569A (zh) 2019-01-31 2020-01-30 检测神经变性疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510593175.6A Pending CN120870569A (zh) 2019-01-31 2020-01-30 检测神经变性疾病的方法

Country Status (6)

Country Link
US (1) US20220397580A1 (enExample)
EP (1) EP3918327A4 (enExample)
JP (2) JP2022519583A (enExample)
CN (2) CN113614531A (enExample)
SG (1) SG11202107238UA (enExample)
WO (1) WO2020157705A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232108A1 (zh) * 2022-06-02 2023-12-07 浙江大学医学院附属第一医院 诊断及鉴别诊断非阿尔兹海默病认知障碍的方法、系统、组合物和试剂盒
CN118348260A (zh) * 2024-05-13 2024-07-16 香港中文大学（深圳） 一种帕金森病诊断标志物组合及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120121584A (zh) 2019-01-31 2025-06-10 新加坡国立大学 传感器芯片及其方法
EP4428245A4 (en) * 2021-11-04 2025-04-02 Toppan Holdings Inc. Method for detecting amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, kit for detection of amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, and method for evaluating accumulation level of amyloid-beta in brain
WO2025117465A1 (en) * 2023-11-27 2025-06-05 New York University Tau is a low affinity receptor of glucocorticoid and needed for glucocorticoid-caused bone loss
WO2025122650A1 (en) * 2023-12-04 2025-06-12 Sunbird Bio, Inc. Extracellular vesicle-based biomarker detection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256793A1 (en) * 2011-10-14 2014-09-11 National University Corporation Hokkaido University MEDICAMENT FOR DISEASES ASSOCIATED WITH AMYLOID beta AND SCREENING THEREOF
WO2015061634A2 (en) * 2013-10-24 2015-04-30 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
CN106062559A (zh) * 2014-06-27 2016-10-26 北京新源长青生物科技有限公司 用于富集cns来源的外泌体的方法
WO2017087467A1 (en) * 2015-11-20 2017-05-26 Exosome Sciences, Inc. Exosomal tau as a biomarker for brain disorders
WO2017124000A1 (en) * 2016-01-14 2017-07-20 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
CN107576805A (zh) * 2010-08-11 2018-01-12 公共救济事业局-巴黎医院 诊断神经变性疾病的方法
US20180238910A1 (en) * 2017-02-22 2018-08-23 Korea Institute Of Science And Technology Methods for providing information relevant to diagnosis of neurodegenerative disorder
WO2018218090A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307890A1 (en) * 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107576805A (zh) * 2010-08-11 2018-01-12 公共救济事业局-巴黎医院 诊断神经变性疾病的方法
US20140256793A1 (en) * 2011-10-14 2014-09-11 National University Corporation Hokkaido University MEDICAMENT FOR DISEASES ASSOCIATED WITH AMYLOID beta AND SCREENING THEREOF
WO2015061634A2 (en) * 2013-10-24 2015-04-30 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
CN106062559A (zh) * 2014-06-27 2016-10-26 北京新源长青生物科技有限公司 用于富集cns来源的外泌体的方法
WO2017087467A1 (en) * 2015-11-20 2017-05-26 Exosome Sciences, Inc. Exosomal tau as a biomarker for brain disorders
WO2017124000A1 (en) * 2016-01-14 2017-07-20 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
US20190025330A1 (en) * 2016-01-14 2019-01-24 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
US20180238910A1 (en) * 2017-02-22 2018-08-23 Korea Institute Of Science And Technology Methods for providing information relevant to diagnosis of neurodegenerative disorder
WO2018218090A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
US20180340945A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
中国科学技术协会: "2012-2013人体解剖与组织胚胎学学科发展报告", 30 April 2014, 中国科学技术出版社, pages: 77 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232108A1 (zh) * 2022-06-02 2023-12-07 浙江大学医学院附属第一医院 诊断及鉴别诊断非阿尔兹海默病认知障碍的方法、系统、组合物和试剂盒
CN118348260A (zh) * 2024-05-13 2024-07-16 香港中文大学（深圳） 一种帕金森病诊断标志物组合及其应用
CN118348260B (zh) * 2024-05-13 2025-02-25 香港中文大学（深圳） 一种帕金森病诊断标志物组合及其应用

Also Published As

Publication number Publication date
US20220397580A1 (en) 2022-12-15
JP2022519583A (ja) 2022-03-24
JP2025029000A (ja) 2025-03-05
EP3918327A4 (en) 2022-11-23
WO2020157705A1 (en) 2020-08-06
CN120870569A (zh) 2025-10-31
EP3918327A1 (en) 2021-12-08
SG11202107238UA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
Lim et al. Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
CN113614531A (zh) 检测神经变性疾病的方法
CN108369179B (zh) 纳米囊泡的多重表型分析
US10557847B2 (en) Nano-plasmonic sensor for exosome detection
CN113412422B (zh) 传感器芯片及其方法
Zhang et al. Sensitive signal amplifying a diagnostic biochip based on a biomimetic periodic nanostructure for detecting cancer exosomes
US20230160809A1 (en) Methods and systems of enhancing optical signals of extracellular vesicles
US12613188B2 (en) Methods and systems of enhancing electromagnetic radiation signals from extracellular vesicles
CN115244386B (zh) 用于表征纳米囊泡及其结合或缔合的靶标的方法和装置
KR102953357B1 (ko) 센서 칩 및 그의 방법
Liu et al. A urine detection chip for the analysis of urinary cells and extracellular vesicles for bladder cancer screening
Yan Plasmonic Biosensor Platforms for Molecular Analy-ses of Circulating Extracellular Vesicles
WO2024206493A1 (en) Molecular analysis of extracellular vesicles (evs) for the detection of idiopathic pulmonary fibrosis
WO2024155814A2 (en) Method of detecting disease-associated markers in a liquid biopsy sample using extracellular vesicles
JP2025524969A (ja) 細胞外小胞からの電磁放射線シグナルを増強する方法およびシステム
WO2025080712A1 (en) Plasmon-enhanced biosensing of extracellular vesicles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Singapore, Singapore City

Applicant after: NATIONAL University OF SINGAPORE

Applicant after: NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) Pte. Ltd.

Address before: Singapore, Singapore City

Applicant before: NATIONAL University OF SINGAPORE

Applicant before: NAT UNIVERSITY HOSPITAL SINGAPORE Pte. Ltd.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20211105

RJ01 Rejection of invention patent application after publication